

Quarter End Statement of Investments

1st Quarter as at March 31, 2022

Industry Allocation	% of Net Asset Value	Top 25 Holdings	% of Net Asset Value
Medical Equipment and Services	44.77%	AbbVie Inc.	2.50%
Pharmaceuticals and Biotechnology	31.82%	Universal Health Services, Inc. (Class B)	2.34%
Health Care Providers	23.06%	Regeneron Pharmaceuticals, Inc.	2.31%
Cash & Cash Equivalents	0.31%	Molina Healthcare, Inc.	2.19%
Total	99.96%	Cigna Corporation	2.18%
Other Assets and Liabilities	0.04%	UnitedHealth Group Incorporated	2.12%
Total Net Asset Value	100.00%	Hologic, Inc.	2.10%
		The Cooper Companies, Inc.	2.08%
		HCA Healthcare, Inc.	2.04%
		Organon & Co.	1.92%
		Henry Schein, Inc.	1.88%
		Thermo Fisher Scientific Inc.	1.85%
		Encompass Health Corporation	1.82%
		Envista Holdings Corporation	1.81%
		Laboratory Corporation of America Holdings	1.75%
		Quidel Corporation	1.74%
		Eli Lilly and Company	1.73%
		IQVIA Holdings Inc.	1.71%
		Steris Plc	1.66%
		Quest Diagnostics Incorporated	1.65%
		Sage Therapeutics, Inc.	1.63%
		Tandem Diabetes Care, Inc.	1.61%
		Bio-Rad Laboratories, Inc. (Class A)	1.56%
		Danaher Corporation	1.49%
		Vertex Pharmaceuticals Incorporated	1.49%
		Total Net Asset Value	\$17,123,238

Commissions, management fees and expenses all may be associated with ETF investments. Please carefully read the prospectus of the ETF before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated. The Quarter End Statement of Investments may change due to the ETF's ongoing portfolio transactions. Updates are available quarterly. Data is as of March 31, 2022 (unaudited).